<DOC>
	<DOCNO>NCT01813474</DOCNO>
	<brief_summary>The objective study investigate safety tolerability olaparib tablet give orally Japanese patient advance solid malignancy . In addition , pharmacokinetic profile , MTD ( possible ) efficacy olaparib investigate .</brief_summary>
	<brief_title>Investigate Safety Tolerability Olaparib Tablet Japanese Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description>MTD - maximum tolerate dose</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Subjects diagnose advanced solid malignancy refractory standard therapy standard therapy exists . Subjects overall good overall general condition . Subjects agree hospitalisation start olaparib multiple dose period day 15 . Evidence nonchildbearing status woman childbearing potential , postmenopausal status . Subjects least one lesion ( measurable and/or nonmeasurable ) accurately assess CT/MRI baseline follow visit Subjects receive previous treatment PARP ( poly adenosine diphosphateribose polymerase ) inhibitor , include olaparib . Subjects receive inhibitor CYP3A4 ( cytochrome P450 3A4 ) . Subjects symptomatic uncontrolled brain metastasis . Subjects myelodysplastic syndrome/acute myeloid leukaemia . Subjects know hypersensitivity olaparib excipients product .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Solid Malignancies</keyword>
</DOC>